This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Facts about Interleukin-18-binding protein.
.
Human | |
---|---|
Gene Name: | IL18BP |
Uniprot: | O95998 |
Entrez: | 10068 |
Belongs to: |
---|
No superfamily |
IL18 BPa; IL-18 BPa; IL18BP; IL-18BP; IL18BPa; interleukin 18 binding protein; interleukin-18-binding protein; MC51L-53L-54L homolog gene product; tadekinig-alfa
Mass (kDA):
21.099 kDA
Human | |
---|---|
Location: | 11q13.4 |
Sequence: | 11; NC_000011.10 (71997944..72002919) |
Strongly expressed in heart, lung, placenta and spleen.
Secreted.
This article will answer your questions about the IL18BP fibrosis marker. This article will describe the function and inhibitory effect of IL-18BP on IFNg. It can be used in clinical research settings such as cancer and inflammatory bowel disease. Before we get into the uses of IL-18BP let's first review its functions and what they do.
The IL-18BP marker, a unique protein, was discovered during a search for soluble receptors. It is a constitutively secreted protein with an unusual affinity for IL-18, present in serum at a 20-fold molar excess. Although IL-18BP may contribute to the blunting of the Th2 response to foreign organisms and to reducing the inflammatory response to routine infections, it does not correspond to the IL-18 receptor's extracellular ligand binding domain and is encoded by a separate gene.
The IL-18BP gene inhibits IL-17's effects on osteoclast development. It decreases osteoclast -inducing molecules like RANKL in serum and serum. It may also have therapeutic potential for RA. It is not yet known how IL-18BP acts in RA. However, it has been shown to inhibit osteoclast formation.
It is important to remember that antibodies to IL-18BP don't only affect human cells. It has been shown that antibodies to IL-18BP can be reacted by human antibodies in a variety different conditions, including immunofluorescence IHC, molecular biology, and molecular biochemistry. The IL-18BP marker has been shown to be useful in determining inflammatory response. Boster Bio anti-IL-18BP antibody is recommended for clinical trials that test the IL-18BP marker.
During a viral infection known as Molluscum contagiosum the human IL-18BP is naturally eliminated. Large viral particles can be found embedded in epithelial tissue of people infected. Because the virus lacks immunological and inflammatory cells, the immune response is not triggered. The amino acid sequence of the IL-18BP protein is very similar to that of the poxvirus gene.
IL-18BP, a cytokine, plays an important role within immunology. Its primary function it to stimulate lymphocytes in producing IFN-g and to regulate cell activity. It also stimulates the transcription and activation of several inflammatory gene, which are key factors in the inflammatory reaction. Knowing the patient's IL-18BP levels will allow you to make the best treatment decisions.
The ELISA test was used to measure the secretion of various cytokines including CCL5, CCL5 and CXCL9. The culture medium was adjusted slightly to adjust the results for RANKL (or IL-18BP). The ELISA kit was also used to measure the secretion of MMP-3 and MMP-13.
The IL-18BP proinflammatory cytokine IL-18 is inhibited by the IL-18BP protein encoded from the gene IL18. It blocks IL-18 from binding its receptor and inhibits its stimulation of IFN-gamma- and T-helper-type 1 immune responses. This protein is expressed in mononuclear cells and is found at elevated levels in the intestinal tissues of Crohn's disease patients. Hepatitis, Molluscum contagiosum, Fulminant Viral disease, and hepatitis are all other diseases that can be associated with IL-18BP.
IL-18BP regulates Th2 & Th27 responses and alleviates the effects from cardiac ischemia/reperfusion. IL-18BP also regulates Th2 cell differentiation. Inflammasome-activated IL-18BP is secreted from monocyte/macrophage cells. It reduces the activity and histological scores of collagen-induced arthritis.
Although its spatially-limited function is important in the control of the spread of infection, it has not been fully understood. IL-18's role is to aid the innate immune system in fighting infection. This is done by controlling the release IL-18 in lymphatic tissues. It regulates the spread and spread of infection through its innate regulation of IFNg. It may also cause tissue damage. This study suggests that IL-18BP may play a local function that has not been explored in chronic inflammatory diseases.
Many suppliers sell antibodies against IL-18BP. Boster Bio products offer antibodies against IL-18BP in ELISA and WB. Boster Bio Anti IL-18BP antibodies remain stable at four and -20 degrees Celsius. Antibodies can be stored at -20degC up to one year, and in the freezer up to a month. Antibodies come with or without the use of blocking peptides. The price of the blocking peptide depends on the length and type of immunogen.
In mouse models of colitis, the effects of IL-18BP have been investigated. Mice lacking NLRP3/NLRP6 are more likely to develop colitis. The disease-induced metabolic condition can be prevented by blocking IL-18BP. The effects are however limited. This protein plays an essential role in heart disease prevention.
One approach to the problem is to use IL-18BP as a fibrotic marker. One approach involves the measurement of the fibrosis marker in a patient's lung tissue, a process known as immunohistochemistry. Serum levels of IL-18BP were detected in lung tissues from IPF and control patients. This technique identifies the presence of IL-18BP in lung tissues and reveals an inverse correlation between IL-18BP expression and %DLco and %FVC.
In this study, researchers used a mouse model to determine whether IL-18BP promotes fibrosis by inhibiting interleukin-37 (IL-37). Although IL-377 is known to be protective against interstitial pulmonary Disease, this inflammatory marker could have an opposite effect and promote fibrosis. In addition, the inflammatory response to IL-18BP is associated with an increase in lung hydroxyproline.
Using IL-18BP to monitor the progression and progression of a rapidly progressing disease is another effective way. The protein is secreted into the bloodstream and has a high affinity to IL-18. By inhibiting IL-18BP, the disease progression is slowed down. IL-18BP also suppresses the immune response to infection.
A study found that patients with IPF who had high serum levels of IL-18BP had poor prognosis. Patients with higher serum levels of IL-18BP had a lower chance of having a reduced forced vital capacity and a poorer prognosis in multivariate models. Furthermore, IL-18BP expression in the lungs was positively correlated with pulmonary hydroxyproline.
In conclusion, the authors emphasize the need for better predictive biomarkers to help IPF patients. They discuss the need for a better biomarker to help with early diagnosis and better prognosis. They present their hypothesis and describe the methods used to evaluate IL-18BP as a fibrosis marker. Further research will be beneficial. Once this is established, IL-18BP could help diagnose IPF earlier and improve the disease prognosis in IPF patients.
BoSTER Bio uses IL-18BP to help determine a patient's stage. It is involved in the regulation and progression of infection in lymphoid tissue, such a lung. As the disease progresses it is seen that this local interface is more strongly supported in lung tissues. There has also been evidence of the potential for tissue damage by IFNg.
Several structural and molecular features of IL-18BP provide a detailed insight into the binding mechanism. Its binding area is composed of hydrophobic spots that have matching electrostatic-ion pairs. Residues K130 to M96, E42 to E42 and L189 in IL-18BP contain electrostatic ion couples that are essential for the binding process. Furthermore, the Nterminal bstrand contains a hydrophobic area of E42.
Human IL18BPa/IL-18BPc can inhibit IL-18 induced IFNg up to 50% at equimolar levels. This is quite low in comparison to the fivefold increase in molarity required to inhibit half the activity soluble receptors. The slow rate of IL18BPa/IL-18BPc may be due to the large interaction site they have with IL18. 1170 A is also buried by IL18.
Anti-IL-12 Ab significantly inhibited TSST-1-induced IFN-g, but did not affect the level of IFN-g produced in response to SEB. TNFbp and IL-18BP do not inhibit IL-12, IL-1Ra. They also have no effect on IL-8 synthesis, which suggests that IL-18BP may play a secondary role in the induction of IFN-g.
IL-18BP may play a role in schizophrenia, but the mechanism is not clear yet. Interleukin-18 plays a role in several inflammatory processes. An abnormality in IL-18BP may contribute to schizophrenia. Further research is needed in order to understand how IL-18BP acts in this inflammatory process. It could help us find a new treatment to schizophrenia. It will be helpful to understand the effects of IL-18BP on the inflammatory response and cellular reactivity.
These results support the use IL-18BP in INFg inhibition. This compound blocks hIL-18-induced IFN-g production by inhibiting the formation of the complex. The molecule was cloned into an altered pET28b expression vector. ELISA was used for the evaluation of its cytotoxic activities. The new drug could be used to treat a wide variety of diseases.
IL-18BP acts as a neutralizing agent and modulates IL-18 bioactivity. It binds IL-18 to high affinity and inhibits the interaction with its receptor. It is found in serum in high amounts in healthy individuals and seems to be modulated all through human life. It is important to understand how IL-18BP works in the immune system so that it can be used as an effective treatment.
PMID: 10023777 by Novick D., et al. Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response.
PMID: 10094485 by Aizawa Y., et al. Cloning and expression of interleukin-18 binding protein.